The study design is described in Ref. [7]. In summary, this 2-center, randomized controlled, parallel group study enrolled 41 patients with T1DM for at least 2 years. The patients were aged 26 to 60 years, with a hemoglobin A_1c (HbA_1c) level below 10%, and treated with MDI and SMBG without any previous experience of CSII or CGMS technologies. Participants completed a 2-week run-in period, during which they demonstrated tolerance to wearing the sensor and compliance with a blinded CGMS and were randomly allocated to either the AHCL therapy (n=20, 49%) or continuation of MDI and SMBG therapy (n=21, 51%). Of these, 4 (10%) participants randomized to the MDI+SMBG group withdrew from the study: 3 (75%) immediately after randomization were not satisfied with group allocation, and 1 (25%) became pregnant during the study. The other 37 (90%) participants completed the 3-month study.

The first part of the analysis aimed and checking the psychological parameters of all the patients who enrolled in the study and comparing them with norms for the general population. We wanted to check whether the patients have any special characteristics that encouraged them to, on the one hand, not use modern technologies for many years and, on the other hand, decide to take part in the research project.

The second part of the analysis aimed at verifying whether after 3 months of the study, the AHCL group in which the MiniMed 780G AHCL insulin pump was introduced became different in terms of psychological parameters from the group that continued the previous method of treatment based on MDI and SMBG. We also checked whether the QoL with diabetes changed between the 2 groups.

Participants’ psychological parameters and QoL were assessed with the following set of questionnaires at baseline and at the end of the study:

For comparisons with general Polish healthy population and the general Polish population of patients with diabetes, we used data collected by the Polish Test Laboratory of the Polish Psychology Association [19-27]. For each test, there was a representative group from the Polish population selected and examined by the psychological team. We chose data for healthy controls and patients with diabetes, stratified by age and sex, were appropriate, including the data provided by PTP statistical parameters (mean, SD, number of participants examined, etc), and we used proper statistical calculations for such analysis.

The study was approved by the bioethics committee (no. 1072.61201.8.2020, date May 28, 2020, trial registry no. NCT04616391). All patients provided written informed consent to participate in this study. The collected data were stored anonymously in an encrypted disc in the hospital according to bioethics committee recommendations. The participants did not receive any financial compensation for participation in the study.

To assess differences between the psychological scores for our group and the general population, a test for 2 means was used. To compare 2 independent variables, the Student or Welch t test for normally distributed (the Shapiro-Wilk test) continuous variables was performed, otherwise the Mann-Whitney U test was conducted. To compare 2 dependent groups, the paired t test or the Wilcoxon signed-rank test, when appropriate, was used. To test for the effect of treatment allocation on psychological outcomes, analysis of covariance (ANCOVA) was conducted, adjusting for treatment arm and baseline values. Once the significant interactions were confirmed, we included them into the model and then estimated the adjusted mean difference between the treatment arms (we centered the baseline value on the mean, and then the estimate in the arm was the adjusted mean difference between the treatment groups). When the ANCOVA assumption was not met, we performed the Wilcoxon rank-sum test. Analyses were performed with R version 4.1.0 and R Studio version 1.3.959 (R Core Team and the R Foundation for Statistical Computing).

Glycemic outcomes of the transition study have been presented previously [7] and include the time spent in target (time in range, TIR), which increased from mean 69.3% (SD 12.3%) at baseline to mean 85.0% (SD 6.3%) at 3 months in the AHCL group, while remaining unchanged in the control group: treatment effect 21.5% (95% CI 15.7%-27.3%), P<.001. The time below range (TBR; <70 mg/dL) decreased from mean 8.7% (SD 7.3%) to mean 2.1% (SD 1.7%) in the AHCL group and remained unchanged in the MDI+SMBG group: treatment effect mean –4.4% (95% CI –7.4% to –2.1%), P<.001 [7]. Baseline characteristics of the participants are presented in Table 1.

A comparison of the study participants with the general healthy population is presented here.

In the analysis, we observed that the T1DM group of 37 patients (study population), who volunteered to participate in our study, differed in many aspects of psychological parameters from the general healthy population.

Although the general level of stress in the study population measured with the PSS-10 was significantly higher in our study population than in the general population (mean 6.62, SD 7.50 vs mean 22.14, SD 4.27, P<.001), the coping strategies used by our study population turned out to be more effective in many aspects. In difficult and stressful situations, our study population is less likely to focus on emotions compared to the general population (mean 45.16, SD 9.94 vs mean 36.94, SD 10.65, P<.001) and does not avoid confrontation with a difficult situation (mean 19.11, SD 5.51 vs mean 16.34, SD 4.40, P=.002), as indicated by CISS results. Brief-COPE results revealed that the participants are much more active in coping with stressful events compared to the general population (mean 1.57, SD 0.79 vs mean 2.22, SD 0.69, P=.003) and are more effective in planning how to manage a stressful event (mean 1.89, SD 0.79 vs mean 2.30, SD 0.69, P=.005). Additionally, they more often use positive reframing compared to the general population (mean 1.67, SD 0.77 vs mean 1.89, SD 0.54, P=.020) and a sense of humor (mean 0.82, SD 0.78 vs mean 1.16, SD 0.67, P=.003) and more easily accept a stressful situation (mean 1.78, SD 0.77 vs mean 2.11, SD 0.63, P=.002), although they tend to experience more negative emotions, which they try to let go of (mean 1.01, SD 0.69 vs mean 1.30, SD 0.67, P=.011). This in turn gives the patients with T1DM in our study population a significantly higher level of self-efficacy, as measured with the GSES (mean 27.32, SD 5.32 vs mean 31.08, SD 2.99, P<.001).

Worth noticing is the observation that only women from the study population (n=6, 16%) aged 41-54 years had a higher level of state anxiety than people from the general population, as measured with the STAI (mean 47.80, SD 9.78 vs mean 39.50, SD9.27, P=.034).

When analyzing the attitude of the patients toward doctors and toward the chronic illness itself, it turned out that the study population accept their illness significantly more than patients with diabetes from the general population, as indicated by AIS scores (mean 24.81, SD 7.09 vs mean 32.17, SD 5.96, P<.001). Interestingly, the patients from our study have less internal control over health, that is, they feel that their health does not depend on them as much as expressed by people from the general population. This was indicated in both age groups (26-35 years: mean 24.81, SD 7.09 vs mean 32.17, SD 5.96, P<.001; >35 years: mean 24.87, SD 5.71 vs mean 23.57, SD 2.37, P=.012). Furthermore, our study participants aged 26-35 years feel significantly more that their health depends on others, especially on their doctors and medical personnel, compared to people from the general population (mean 20.00, SD 4.61 vs mean 24.50, SD 4.07, P=.003). In turn, the study participants older than 35 years often consider their health status as the result of chance compared to people from the general population (mean 21.05, SD 6.29 vs mean 17.86, SD 6.18, P=.008). In terms of their expectations toward doctors (PRF), the study participants expressed less need to gain information (mean 9.68, SD 2.95 vs mean 8.09, SD 2.86, P=.001) and explanations about their health (mean 10.09, SD 2.79 vs mean 8.2, SD 3.27, P=.001) that usually people from the general healthy population expect from their doctors.

The overall life satisfaction of patients with T1DM who participated in the study seems to be similar to that declared by people from the general healthy population (mean 20.37, SD 5.32 vs mean 21.46, SD 4.53, P=.161). All these comparisons are presented in Table 2.

A comparison between the 2 groups created within the study patients with T1DM after randomization and after 3 months from transition (AHCL group with the control group) at the end of the study are presented here.

The AHCL group reported an increase in the QoL in 4 scales: feeling well, which indicates global well-being (score 2.3, 95% CI 0.1-4.6, P=.042); working, which is a manifestation of work satisfaction, flexibility at work, and the possibility to fulfill all tasks at work (score 2.8, 95% CI 0.7-4.9, P=.012); eating as I would like, which shows emotional freedom in terms of eating, pleasure connected with eating, and the flexibility of eating (score 3.1, 95% CI 0.8-5.4, P=.011); and doing normal things, which shows the emotional subjective feeling of a given person, that they may function normally, not being limited by the disease (score 2.8; 95% CI 0.2-5.4, P=.034). The level of anxiety significantly decreased in the AHCL group: STAI X1 scores showed that the AHCL group was less anxious in a given moment (score –6.8, 95% CI –11.8 to –1.8, P=.009), as confirmed by STAI X1 stens (score –1.4, 95% CI –2.5 to –0.3, P=.013). In addition, STAI X2 scores showed that the general, long-term level of anxiety turned out to be lower in the AHCL group (score –3.5, 95% CI –6.5 to –0.5, P=.022). Furthermore, the AHCL group became more emotion oriented, which shows they unblocked their emotions when in a stressful situation (CISS E; score 1.1, 95% CI –2.2 to 0.0, P=.043) and significantly less tend to self-blame after 3 months of the study (score –0.5, 95% CI –0.9 to –0.09, P=.020). All between-groups differences were adjusted for baseline values (Table 3).

Our study aimed at evaluating adult patients with T1DM who after many years of MDI treatment and SMBG using a blood glucose meter (BGM) had their treatment changed directly to the MiniMed 780G AHCL system. First, we showed that in comparison to the general healthy population, our studied population before the transition was characterized by a higher level of stress but at the same time higher self-efficacy and better coping strategies. Furthermore, we revealed that during the first 3 months of the treatment change from MDI and SMBG directly to the AHCL system, the patients experienced improvement in various aspects of QoL and also experienced a decrease in anxiety and the feeling of guilt. In addition, the mental well-being of the transitioned patients did not deteriorate in any of the examined patients. In the control group, the examined parameters stayed unchanged.

We decided to carry out a 2-stage analysis: first to check the general psychological parameters of all the patients with T1DM who enrolled in the study. This was an interesting population of patients who had never before decided to use modern technologies in their diabetes management and now they had decided to overcome their earlier habits and attitudes toward modern technologies. We wanted to make a comparison of their psychological characteristics to the general Polish population and then check the between-group differences after the randomization process and 3-month study, when one part of the group underwent the transition in treatment and the other part became the control group, without a change in treatment. From a psychological point of view, this is a significant change in terms of diabetes control—the level of responsibility of glucose level control, calculation of the insulin dosage, and reactions to the blood glucose level resulting from a proper medical decision 24 hours a day shifted to the insulin pump, which is highly automatized. Thanks to the automation, the pump reacts independently of the patient to glucose level changes, protecting the patient from both hypo- and hyperglycemia. This requires a change in the control level that the patients got used to over many years of treatment [10,11]. To the best of our knowledge, there is no study carried out so far that has examined in a direct way the psychological reaction to a direct change of treatment from the traditional way of treatment to the most modern one available.

Another change concerns the self-image. Treatment with insulin injections with the use of a pen and monitoring the glucose blood level with a traditional BGM usually require several measurements and a few injections per day. The MiniMed 780G AHCL system is connected with a permanent personal insulin pump, sensor, transmitter, CGMS, and infusion set being placed on the body. The system has alarms set, which can be heard by people around. We assumed that for some patients, this kind of change might not have any special meaning and they would get used to it easily, but for others, it could be connected with the need to overcome some level of resistance, discomfort, or even shame resulting from—for some of the patients—the specific coming out of being diabetic, for example, in the workplace [27,28,30-33]. Nowadays, children and adolescents are usually treated with modern technologies (personal insulin pump, CGMS) immediately after being diagnosed or soon after the diagnosis. The same is offered to adults diagnosed with T1DM, although in this group of patients, finances are often a limitation. The patients in our study were treated with traditional intensive insulin therapy for many years before—some of them for over 30 years. They developed their identity around the traditional method of treatment, and the possibility to use the MiniMed 780G insulin pump was a real-life breakthrough [30,31].

Analyzing the initial psychological parameters of the patients who enrolled in the study, we observed that this group of patients had good coping strategies to deal with stress—to some extent even more efficient than the general population. We believe that the patients worked out stress adjustment during many years of dealing with diabetes, and at the same time, perhaps those psychological resources encouraged them to apply for participation in the study and then allowed optimal adjustment to the new method of treatment. Our results also indicate that in terms of diabetes education, the patients expressed no special needs apart from learning how to use the new pump/CGMS.

We applied as many as 10 questionnaires to make sure that we properly monitored various aspects of the patients’ psychological functioning. None of the patients from the study reacted negatively, with aroused levels of stress or inconvenience. The level of stress, ways of dealing with difficult situations, and acceptance of the illness did not have any negative response in comparison to the control group after 3 months of treatment. In addition, after the 3-month period of application of the MiniMed 780G AHCL system, the level of anxiety—both state anxiety and trait anxiety—was significantly lower than in the control group. This is especially important when we consider the fact that for many patients with T1DM, the source of constant anxiety is the possibility of having hypoglycemia during various daily activities, as indicated by researchers [32-35], but also, they often face fear connected with the possibility of developing late complications [36]. Thus, the decrease in anxiety may result not only from the protection from hypoglycemia, which is ensured by the closed-loop system, but also from the awareness that the TIR, which was significantly higher in this group, allows the patients to get more confidence in their long-term better health and lower risk of late complications.

Essential is the significant increase in the QoL of the AHCL group in 4 important areas: feeling well, working, eating as I would like, and doing normal things.

Knowledge about the QoL is important for understanding the consequences of illness and treatment and for medical decision-making across age groups and cultures. The QoL is an important end point in medical and health research, and QoL research involves a variety of target groups and research designs [37]. Numerous demographic and psychosocial factors influence the QoL. Studies of clinical and educational interventions suggest that improving patients' health status and perceived ability to control their disease results in improved QoL [38-40].

Our study revealed that not only did a change in the treatment method from MDI and SMBG with a BGM directly to the MiniMed 780G AHCL system not worsen the subjective assessment of the QoL of the patients, but they also felt better in a significant way in general, experienced improvement in their working place, felt more “normal and free” in their everyday eating, and could more easily state that they can do normal things. In addition, the patients from the AHCL group experienced less feelings of guilt at the end of the study and could more easily be in contact with their emotions in stressful situations. This may relate to the fact that the improvement in diabetes control and shift in responsibility for glucose level results from the patient to the highly automatized insulin pump unblocked the burden of responsibility the patients had to deal with before and allowed them to be more focused on emotions connected with a given life situation and not so much on diabetes.

All the metabolic parameters and changes obtained during the study in terms of glucose control (TIR, HbA_1c, etc) are presented in Ref. [7].

One limitation of the study was the short period of observation (3 months), but as the study continues, we will keep on monitoring the psychological parameters and conduct further analyses after a year of study progress. In addition, when drawing conclusions connected with possible psychological outcomes connected to transition from MDI and SMBG treatment directly to the MiniMed780G AHCL system in patients with T1DM naive to technology, we must consider the fact that the patients in our studied group were highly motivated and had good psychological resources. Furthermore, they had regular control visits and could easily consult with the medical team about all their doubts (the frequency of visits was higher in comparison to standard therapy). In real-life conditions, this is not always easily available.

Another limiting factor was the number of comparisons made, and it is likely that type 1 errors may have occurred. Considering psychological parameter change/analysis, the studied group was relatively small. In addition, questionnaires were not administered in random order, so patient fatigue may have influenced the results.

The results indicate that the patients who decided to take part in the transition study were characterized by a higher level of stress than the general healthy population but had better coping strategies and self-efficacy. Furthermore, we can conclude that transition from MDI and SMBG treatment directly to the MiniMed 780G AHCL system in patients with T1DM naive to technology can not only in a significant way improve glucose control and metabolic parameters fast as after 3 months but also in a noticeable way improve the well-being of patients, giving them more comfort, freedom, and life flexibility. The rapidity of these changes suggests that they may be related to significant improvement in glycemic outcomes but also significantly less burdened diabetes self-management.